Proposal of a functional prognostic scale in mexican patients with guillain-barré syndrome

• Edwin S. Vargas-Cañas ^[1] ; Juan C. López Hernández ^[2] ; Sandra Badial-Ochoa ^[1] ; Javier Andrés Galnares Olalde ^[1] ; Victoria Martínez-Ángeles ^[1] ; Elliot Hernández-Angelino ^[3] ; David Domínguez-Romero ^[3] ; Raúl Medina-Rioja ^[3]
  1. [1] Instituto Nacional de Neurología y Neurocirugía

     Instituto Nacional de Neurología y Neurocirugía

     México

     
  2. [2] Neuromuscular Diseases Clinic, Emergency Department, Instituto Nacional de Neurología y Neurocirugía "Dr. Manuel Velasco Suárez", Mexico City, Mexico
  3. [3] Emergency Department Instituto Nacional de Neurología y Neurocirugía "Dr. Manuel Velasco Suárez", Mexico City, Mexico

  Mostrar afiliaciones +
• Localización: Revista de investigación clínica, ISSN 0034-8376, ISSN-e 2564-8896, Vol. 76, Nº. 6, 2024, págs. 253-261
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • There is currently no prognostic scale for patients with Guillain-Barré syndrome (GBS) in the Mexican population. Objective: The objective of the study was to examine the factors associated with functional prognosis by proposing short-term and long-term prognostic scales. Methods: Prospective cohort of patients with GBS at an academic medical center, with neuroconduction study and 6-month follow-up. Through logistic regression, we evaluated clinical and paraclinical variables, and the results are expressed as odds ratios 95% confidence intervals [CIs]). We used a scale to predict poor functional prognosis. The performance of the scale was assessed using the area under the curve (AUC). Results: A total of 259 patients (age 46.1 ± 16.1 years) were included in the study; 38.6% had a history of diarrhea, and 42.8% had an axonal variant. The rates of poor functional prognosis were 36.6% and 22.7% at 3 and 6 months of follow-up, respectively. The following variables were included in the univariate logistic regression: age ≥ 70 years, history of diarrhea, axonal variant, and Medical Research Council score. We performed a prognostic scale (0-9 points), with AUC of 0.81 (95% CI: 0.75-0.86) at 3 months, and 0.82 (95% CI: 0.76-0.87) at 6 months, which was higher than the modified Erasmus Guillain-Barré Outcome Score scale at admission (AUC: 0.75. 95% CI: 0.69-0.81 and AUC: 0.78. 95% CI: 0.72-0.83). Conclusion: The proposed prognostic scale performs well in discerning poor functional prognosis in short- and long-term frames among Mexican patients. (REV INVEST CLIN. 2024;76(6):253-61)